Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And 'Substantial Growth'
Entourage Health Cannabis Reports 9% YoY Increase In Q1 Revenue, Positive EBITDA And 'Substantial Growth'
Canadian cannabis producer and distributor Entourage Health Corp. (TSXV:ENTG) (OTCQX:ETRGF) (FSE:4WE) announced its first quarter financial results on Tuesday for the three months ended March 31, 2024.
加拿大大麻股生產商和分銷商Entourage Health Corp.（TSXV: ENTG）（OTCQX: ETRGF）（FSE：4WE）於2024年3月31日公佈了其第一季度財務業績。
The Toronto-based company reported a total revenue of CA$16.4 million ($12 million) (net revenue of CA$12.7 million, before excise duties and discounts), representing a 9% year-over-year increase.
這家總部位於多倫多的公司報告了總營業收入達到1600萬加幣（1200萬美元）（扣除消費稅和折扣前的淨營業收入爲1270萬加幣），同比增長9%。
"Entourage's first quarter results are a testament to our robust financial health and strategic approach to business operations, positioning us for success throughout 2024," George Scorsis, the company's chair and CEO said. "With defined infrastructure and supply agreements in place, we are well-positioned to continue delivering the accelerated growth we have already seen develop in Q1."
該公司的主席兼首席執行官George Scorsis表示:“Entourage的第一季度業績證明了我們強有力的財務實力和商業運營的戰略方法，這爲我們在整個2024年實現成功奠定了基礎。通過明確的基礎設施和供應協議，我們有能力繼續提供Q1快速增長。”
Q1 2024 Financial Highlights
2024年第一季度財務亮點
- Gross profit before changes in fair value amounted to CA$5.8 million, up from CA$3 million in the prior year's period.
- Gross margin before changes in fair value was 45%, up from 25% in the same quarter of fiscal 2023.
- Loss and comprehensive loss was CA$6.3 million, down from CA$9.5 million in the corresponding quarter of last year.
- EBITDA (non-IFRS measure) came in positive at CA$533, 000 compared to a negative EBITDA of CA$3.9 million in the prior year's period.
- Cash and cash equivalents were CA$9.4 million and working capital was CA$152.9 million as of March 31, 2024, down from CA$11.2 million and up from CA$146.9 million, respectively, during the period ended March 31, 2023.
- 公允價值變動前的毛利潤總額爲580萬加元，而去年同期爲300萬加元。
- 公允價值變動前的毛利率爲45％，而去年同季度的毛利率爲25％。
- 淨虧損及綜合損失爲630萬加元，而去年同期爲950萬加元。
- 調整後的EBITDA (非IFRS度量)爲正值53.3萬加元，而去年同期爲負值390萬加元。
- 截至2024年3月31日，現金及現金等價物爲940萬加元，營運資本爲1.529億加元，分別比截至2023年3月31日的1.12億加元和1.469億加元下降和上升。
As yet another earnings reporting season wraps up it is important to understand what these figures mean for the future of the industry. Hear directly for top executives, investors and policymakers at the 19th Benzinga Cannabis Capital Conference, coming to Chicago this Oct. 8-9. Get your tickets now before prices surge by following this link.
隨着又一個季度業績發佈的結束隨着又一個季度的業績期結束，了解這些數字對行業未來意味着什麼便顯得十分重要。聽取BenZinga大麻資本會議第19屆的高管、投資者和政策制定者的直接觀點，該會議將於今年10月8-9日在芝加哥舉辦，在此鏈接上可以提前獲取門票。
"Our team's relentless focus on efficient execution has led to a solid performance, reflected in improved profitability and a significant increase in EBITDA, marking the first positive quarter," Scorsis continued. "We are also seeing substantial growth in our adult-use business as we continue to announce and launch a range of innovative products across Canada set to generate ongoing interest and excitement among consumers."
Scorsis先生稱：“我們團隊對高效執行的不斷關注帶來了可靠的業績，並體現出盈利能力的提高和EBITDA的大幅增長，這是首個實現收支平衡的季度。隨着我們繼續在加拿大推出一系列創新產品，我們在成年人用途方面也看到了實質性的增長，爲消費者持續激發興趣和興奮。”
ETRGF Price Action
Entourage Health Corp.交易日收盤時，其股票價格上漲了38.6％，達到每股0.0132加元。
Entourage's shares traded 38.6% higher at CA$0.0132 per share at the market close on Friday.
大麻股公司Entourage Health報告稱，2023年毛利潤增長了126％，虧損顯著下降。
Related News
相關新聞資訊
- Cannabis Co. Entourage Health Reports 126% YoY Increase In 2023 Gross Profit, Cuts Losses Significantly
- 加拿大大麻公司Entourage Health Corp.第三季度營業收入同比下降8.8％，但利潤率上升，虧損下降。
- Canadian Cannabis Co. Entourage Health Q3 Revenue Slides 8.8% YoY – But Margins Sore, Losses Decline
- Entourage Health業績公佈Q1營收同比下降4.8%，那麼調整後的EBITDA又如何呢？
- Entourage Health Q1 Revenue Declines 4.8% YoY, What About Adjusted EBITDA?
- Entourage Health一季度營業收入同比下降4.8％，調整後的EBITDA怎麼樣？
譯文內容由第三人軟體翻譯。